title: [Evaluation of the symptomatology and quality of life in functional dyspepsia before and after Helicobacter pylori eradication treatment].
abstract: BACKGROUND
  Whether H. pylori infection plays a role in FD is ill defined; however, it is recommended to prescribe eradication treatment in patients with dyspepsia without alarm symptoms. Results of this advice are controversial, principally due to absence of instruments that provide an objective measure of changes in symptoms and quality of life.
  
  
  OBJECTIVE
  Our aim was to evaluate significant changes in symptom severity and quality of life in patients with functional dyspepsia (FD) following Helicobacter pylori (H. pylori) eradication treatment.
  
  
  METHODS
  We conducted an open clinical trial in adult patients with FD who were H. pylori-positive by means of 14C breath test. Treatment consisted of 2 weeks on lanzoprazole, amoxicillin, and clarithromycin. Score change on the severity of dyspepsia assessment (SODA) test instrument was used to evaluate modifications in symptom severity and quality of life.
  
  
  RESULTS
  One hundred patients were included in this trial; treatment compliance was observed in 77% of these, while cure of H. pylori infection was obtained in 82.7% of patients. Only 11.7% displayed absence of dyspepsia symptoms and improvement in quality of life. No significant changes were obtained in global assessment nor in pain, or symptoms in health perception quality of life when initial SODA scores were compared with after-treatment results.
  
  
  CONCLUSIONS
  There was no improvement of FD symptoms or quality of life after H. pylori eradication treatment.
authors.affiliation: Centro Médico Nacional 20 de Noviembre ISSSTE.
authors.forename: Laura
authors.initials: L
authors.lastname: Ladrón de Guevara
authors.forename: Nicolás Gómez
authors.initials: NG
authors.lastname: Peña-Alfaro
authors.forename: Luis
authors.initials: L
authors.lastname: Padilla
authors.forename: Alejandro
authors.initials: A
authors.lastname: Lichtinger
authors.forename: Siegfried
authors.initials: S
authors.lastname: Figueroa
authors.forename: Ilan
authors.initials: I
authors.lastname: Shapiro
authors.forename: Marc
authors.initials: M
authors.lastname: Rubinstein
authors.forename: Mauricio
authors.initials: M
authors.lastname: Di Silvio
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000382:microbiology* / Q000503:physiopathology*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011788:Quality of Life
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole